The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: A lesson in epitope analysis

Reviews in Medical Virology

Volumn 15, Issue 6, 2005, Pages 365-381

  Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ALPHA HELIX; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENIC VARIATION; ANTIGENICITY; CARBOXY TERMINAL SEQUENCE; CELL FREE SYSTEM; CELLULAR DISTRIBUTION; CHIMERA; CONFORMATIONAL TRANSITION; ELUTION; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHILICITY; IMMUNOREACTIVITY; LIFE CYCLE; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; VIRION; VIRUS ADSORPTION; VIRUS ATTENUATION; VIRUS ENVELOPE; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL FUSION; EPITOPES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; VARIATION (GENETICS);

EID: 27744600607     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.476     Document Type: Review

References (98)

1. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature (Lond) 1997; 387: 426-430.
2. Tan K, Liu J-H, Wang J-H, Shen S, Liu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94: 12303-12308.
3. Malashkevitch VN, Chan DC, Chutowski CT, Kim PS. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci USA 1998; 95: 9134-9139.
4. Caffrey M, Cai M, Kaufman J, et al. Three-dimensional solution of the 44kDa ectodomain of SIV gp41. EMBO J 1998; 17: 4572-4584.
5. Gallaher WR, Henderson LA, Fermin C, et al. Membrane interactions of human immunodeficiency virus: attachment, fusion, and cytopathology. In Advances in Membrane Fluidity; Membrane Interactions of HIV. Wiley-Liss: New York, 1992; 113-142.
6. Buratti E, McLain L, Tisminetzky SG, Cleveland SM, Dimmock NJ, Baralle FE. The neutralizing antibody response against a conserved region of HIV-1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 1998; 79: 2709-2716.
7. Ho DD, Sarngadharan MG, Hirsch MS, et al. Human immunodeficiency virus virus-neutralizing antibodies recognise several conserved domains on the envelope glycoprotein. J Virol 1987; 61: 2024-2028.
8. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, Weiss RA. Neutralization of diverse strains of HIV-1 by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988; 165: 209-215.
9. Chanh TC, Dreesman G, Kanda P, et al. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 1986; 5: 3065-3071.
10. McLain L, Porta C, Lomonossoff GP, Durrani Z, Dimmock NJ. Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses 1995; 11: 327-334.
11. Durrani Z, McInerney TL, McLain L, et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 1998; 220: 93-103.
12. McInerney TL, Brennan FR, Jones TD, Dimmock NJ. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying a HIV-1 peptide. Vaccine 1999; 17: 1359-1368.
13. Newton SMC, Joys TM, Anderson SA, Kennedy RC, Hovi ME, Stocker BAD. Expression and immunogenicity of an 18-residue epitope of HIV-1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol 1995; 146: 203-216.
14. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plant virus. Vaccine 1996; 14: 799-810.
15. Cleveland SM, Buratti E, Jones TD, et al. Immunogenic and antigenic dominance of a non-neutralizing epitope over a highly conserved neutralizing epitope in the gp41 transmembrane envelope glycoprotein of HIV-1: its deletion leads to a strong neutralizing antibody response. Virology 2000; 266: 66-78.
16. Cleveland SM, Jones TD, Dimmock NJ. Properties of a neutralizing antibody that recognises a conformational form of epitope ERDRD in the C-terminal tail of human immunodeficiency virus type 1. J Gen Virol 2000; 81: 1251-1260.
17. Cleveland SM, McLain L, Cheung L, Jones T, Hollier M, Dimmock NJ. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 2003; 84: 591-602.
18. McLain L, Brown JL, Cheung L, et al. Different effects of a single amino acid substitution on three epitopes in the gp41 C-terminal loop of a neutralizing antibody escape mutant of human immunodeficiency virus type 1. Arch Virol 2001; 146: 157-166.
19. Reading SA, Heap CJ, Dimmock NJ. A novel monoclonal antibody specific for the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny. Virology 2003; 315: 362-372.
20. Schultz G. Transmembrane β-barrel proteins. Adv Protein Chem 2003; 63: 47-70.
21. Hollier M, Dimmock NJ. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C and D may exist in two conformations: an analysis of sequence, structure, and function. Virology 2005; 337: 284-296.
22. Deschambeault J, Lalonde J-P, Cervantes-Acpsta G, Lodge R, Cohen EA, Lemay G. Polarized human immunodeficiency virus budded in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. J Virol 1999; 73: 5010-5017.
23. Lodge R, Lalonde J-P, Lemay G, Cohen EA. The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells. EMBO J 1997; 16: 695-705.
24. Ohno H, Aguilar RC, Fournier M-C, Hennecke S, Cosson P, Bonifacino JS. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 1997; 238: 305-315.
25. West JT, Weldon SK, Wyss S, et al. Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J Virol 2002; 76: 3338-3349.
26. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gpl60. Proc Natl Acad Sci USA 1988; 85: 9580-9584.
27. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (Lond) 1985; 313: 277-284.
28. Evans DJ, McKeating JA, Meredith JM, et al. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (Lond) 1989; 339: 385-388.
29. Kalyan NK, Lee S-G, Wilhelm J, et al. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 1994; 12: 753-760.
30. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ. A plant virus-HIV-1 chimera stimulates antibody that neutralizes HIV-1. In Vaccine 96, Brown F, Burton DR, Collier J, Mekalonos J, Norrby E (eds). Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, 1996; 311-316.
31. Cheung LHY. Antibody Specificities Stimulated by Cowpea Mosaic Virus-HIV Chimeras. PhD dissertation, University of Warwick, 2002.
32. Cheung L, McLain L, Hollier MJ, Reading SA, Dimmock NJ. Part of the C-terminal tail of the envelope gp41 transmembrane protein of human immunodeficiency virus type 1 (HIV-1) is exposed on the cell surface and is involved in virus-mediated cell-cell fusion. J Gen Virol 2005; 86: 131-138.
33. Kennedy RC, Henkel RD, Pauletti D, et al. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 1986; 231: 1556-1559.
34. Kennedy RC, Dreesman GR, Chanh TC, et al. Use of resin-bound synthetic peptide for identifying a neutralization antigenic determinant associated with the human immunodeficiency virus envelope. J Biol Chem 1987; 262: 5769-5774.
35. Hifumi E, Mitsuda Y, Ohara K, Uda T. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. J Immunol Methods 2002; 269: 283-298.
36. Hifumi E, Okamoto Y, Uda T. How and why 41S-2 antibody subunits acquire the ability to catalyse decomposition of the conserved sequence of gp41 of HIV-1. Appl Biochem Biotechnol 2000; 83: 209-213.
37. Pincus SH, Messer KG, Hsu S-L. Effect of non-protective vaccination on antibody response to subsequent human immunodeficiency virus infection. J Clin Invest 1994; 93: 140-146.
38. Pincus SH, Messer KG, Schwartz DH, et al. Differences in the antibody response to human immunodeficiency virus type 1 envelope protein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993; 91: 1987-1996.
39. Warren RQ, Wolf H, Schuler KR, et al. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. J Virol 1990; 64: 486-492.
40. Warren RQ, Zajac RA, Boswell RN, Kanda P, Kennedy RC. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in infected individuals grouped according to CD4+ cell levels. J Clin Immunol 1991; 11: 13-21.
41. Goudsmit J, Meloen RH, Brasseur R, Barin F. Human B-cell epitopes of HIV-2 transmembrane protein are similarly spaced as in HIV-1. J AIDS 1989; 2: 297-302.
42. Goudsmit J, Meloen RH, Brasseur R. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 1990; 31: 327-338.
43. Norrby E, Putkonen P, Bottiger B, Utter G, Biberfeld G. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum Retroviruses 1991; 7: 279-285.
44. Vella C, Minor PD, Weller IVD, Jenkins O, Evans D, Almond J. Recognition of poliovirus/HIV chimeras by antisera from individuals with HIV infection. AIDS 1991; 5: 425-430.
45. Ugen KE, Srikantan V, Goedert JJ, Nelson PR, Williams WW, Weiner DB. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. J Infect Dis 1997; 175: 63-69.
46. Broliden P-A, von Gegerfelt A, Clapham P, et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992; 89: 461-465.
47. Abacioglu YH, Fouts TR, Laman JD, et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994; 10: 371-381.
48. Vella C, Ferguson M, Dunn G, et al. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J Gen Virol 1993; 74: 2603-2607.
49. Cleveland SM. HIV-1 Specific Antibody Responses to a Plant Virus-HIV Chimera. PhD dissertation, University of Warwick, 1999.
50. Reading SA. Antibodies to The Envelope Protein of HIV-1. PhD dissertation, University of Warwick, 2003.
51. Wilson IA, Stanfield RL. Antibody-antigen interactions. Curr Opin Struct Biol 1993; 3: 113-118.
52. Laver WG, Air GM, Webster RG, Smith-Gill SJ. Epitopes on protein antigens: misconceptions and realities. Cell 1990; 61: 553-556.
53. Heap CJ, Reading SA, Dimmock NJ. An antibody specific for the C-terminal tail of gp41 of HIV-1 mediates post-attachment neutralization probably through inhibiting virus-cell fusion. J Gen Virol 2005; 86: 1499-1507.
54. Heap CJ. Analysis of HIV-1 Neutralization. University of Warwick, 2004.
55. Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995; 206: 713-717.
56. Spies CP, Ritter GD, Mulligan MJ, Compans RW. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol 1994; 68: 585-591.
57. Mulligan MJ, Yamshchikov GV, Ritter GD, et al. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in certain cell types. J Virol 1992; 66: 3971-3975.
58. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (Lond) 1986; 322: 470-474.
59. Wilk T, Pfeiffer T, Bosch V. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 1992; 189: 167-177.
60. Zingler K, Littman DR. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J Virol 1993; 67: 2824-2831.
61. Jones PLS, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998; 273: 404-409.
62. Lu M, Stoller MO, Wang S, Liu J, Fagan MB, Nunberg JH. Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol 2001; 75: 11146-11156.
63. Follis KE, Larson SJ, Lu M, Nunberg JH. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol 2002; 76: 7356-7362.
64. He Y, Vassell R, Zaitseva M, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77: 1666-1671.
65. Moore JP, McKeating JA, Huang Y, Ashkenazi A, Ho DD. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992; 66: 235-243.
66. Allaway GP, Ryder AM, Beaudry GA, Maddon PJ. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 of gp41. AIDS Res Hum Retroviruses 1993; 9: 581-587.
67. Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus glycoprotein by soluble CD4. J Exp Med 1991; 174: 407-415.
68. Xu J-Y, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immundominant domains of gp41, the transmembrane protein of human deficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991; 65: 4832-4838.
69. Moore JP, Klasse PJ. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and gp120 dissociation. AIDS Res Hum Retroviruses 1992; 8: 443-450.
70. Fu Y-K, Hart TK, Jonak ZL, Bugelski PJ. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120. J Virol 1993; 67: 3818-3825.
71. Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P. Conformational changes induced in the envelope protein of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993; 67: 7383-7393.
72. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunol Today 1996; 17: 239-246.
73. Beaumont T, Broersen C, van Nuenen A, et al. Increased neutralization sensitivity and reduced capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol 2000; 74: 7699-7707.
74. Mbah HA, Burda S, Gorny MK, et al. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J Virol 2001; 75: 7785-7788.
75. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 2002; 18: 1207-1217.
76. Frey S, Marsh M, Günther S, et al. Temperature dependence of cell-cell fusion induced by the envelope of human immunodeficiency virus type 1. J Virol 1995; 69: 1462-1472.
77. Thali M, Moore JP, Furman C, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993; 67: 3978-3988.
78. Sullivan N, Sun Y, Sattentau Q, et al. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-4703.
79. Srivastava KK, Fernandez-Larsson R, Zinkus DM, Robinson HL. Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness. J Virol 1991; 65: 3900-3902.
80. Rieber EP, Federle C, Reiter C, et al. The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis. Proc Natl Acad Sci USA 1992; 89: 10792-10796.
81. McInerney TL, Dimmock NJ. Post-attachment neutralization of a primary strain of HIV-1 in PBMCs is mediated by CD4-specific antibodies but not by a gp120-specific antibody that gives potent standard neutralization. AIDS Res Hum Retroviruses 2001; 17: 1645-1654.
82. Jackson NAC, Levi M, Wahren B, Dimmock NJ. Mechanism of action of a 17 amino acid microantibody specific for the V3 loop that neutralizes free HIV-1 virions. J Gen Virol 1999; 80: 225-236.
83. Armstrong SJ, Dimmock NJ. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: identification of a very early fusion-independent event as a neutralization target. J Gen Virol 1996; 77: 1397-1402.
84. Pelchen-Matthews A, Clapham P, Marsh M. Role of CD4 endocytosis in human immunodeficiency virus. J Virol 1995; 69: 8164-8168.
85. Lu S, Putney SD, Robinson HL. Human immunodeficiency virus entry into T cells: more rapid escape from an anti-V3 loop than an antireceptor antibody. J Virol 1992; 66: 2547-2550.
86. Doranz BJ, Baik SSW, Doms RW. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999; 73: 10346-10358.
87. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide. J Cell Biol 1998; 140: 315-323.
88. Dimmock NJ. Neutralization of animal viruses. Curr Topics Microbiol Immunol 1993; 183: 1-149.
89. Parry N, Fox G, Rowlands D, et al. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature (Lond) 1990; 347: 569-572.
90. Krebs O, Ahl R, Straub OC, Marquardt O. Amino acid changes outside the G-H loop of capsid protein of type O foot-and-mouth disease virus confer resistance to neutralization by anti-peptide G-H serum. Vaccine 1993; 11: 359-362.
91. Thali M, Charles M, Furman C, et al. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 conferred by a gp41 amino acid change. J Virol 1994; 68: 674-680.
92. Watkins MA, Buge S, Aldrich K, et al. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996; 70: 8431-8437.
93. Lafon M, Wiktor TJ, Macfarlan RI. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol 1983; 64: 843-851.
94. Préhaud C, Coulon P, Lafay F, Thiers C, Flamand A. Antigenic site II of the rabies virus glycoprotein: structure and role in virulence. J Virol 1988; 62: 1-7.
95. Flamand A, Raux H, Gaudin Y, Ruigrok RWH. Mechanisms of rabies virus neutralization. Virology 1993; 194: 302-313.
96. Irie T, Kawai A. Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9. J Gen Virol 2002; 83: 3045-3053.
97. Burton DR, Saphire EO, Parren PWHI. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Topics Microbiol Immunol 2001; 260: 109-143.
98. Dimmock NJ, Hardy SA. Valency of antibody binding to virions and its determination by surface plasmon resonance. Rev Med Virol 2004; 14: 123-135.